Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
New words:
accrual, accuracy, addressing, anniversary, Biogen, bronchoconstriction, Brovana, burdensome, cGMP, compound, counterclaimed, counterpart, device, discount, draft, dry, emphysema, fomoterol, framework, France, front, fumarate, GAAP, George, Idec, III, improper, IND, ineffective, investor, isomer, Jean, Kingdom, LABA, leave, lost, mandate, marketplace, meter, Mylan, nebulization, nebulized, Nevada, Nonrefundable, Ohio, Orencia, overhead, PERFOROMIST, promptly, recourse, recovery, refund, retail, Rituxan, salmeterol, Sepracor, Serevent, Solution, Squibb, sued, thereof, turnover, unqualified, unusable
Removed:
acceptability, Anne, assessed, bioavailability, bridge, comparative, enable, fed, Finnegan, Frederick, intended, Medicept, modification, negotiation, Newman, Paul, pharmacokinetic, pivotal, profile, proportion, reliance, resignation, resigned, retained, retaining, Rubin, served, stepped, sufficiency, validation, Walter, workforce
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.3 EX-10.3 License and Supply Agreement
- 10.4 EX-10.4 Ffis Co-promotion Agreement
- 10.5 EX-10.5 Amendment No. 1 to Co-promotion and Marketing Services Agreement
- 10.6 EX-10.6 First Amendment to Exclusive License Agreement
- 10.7 EX-10.7 Amendment No. 3 to Sponsored Research and License Agreement
- 31 EX-31 Section 302 Certification of the Principal Executive Officer and Principal Financial Officer
- 32 EX-32 Section 906 Certification of the Principal Executive Officer and Principal Financial Officer
Related press release
CRTX similar filings
External links